Webinar
Microbiology
CLSI AST FDA Webinar
FDA’s Role in ASTs and Understanding CLSI Breakpoint Decisions
This on-demand webinar will help labs understand the FDA's recognition and identification process of breakpoints for antimicrobial susceptibility (AST) testing and the FDA interpretive Criteria Webpages. Ensure your laboratory grasps how CLSI's breakpoint decisions help:
- Improve AST availability for new antibacterial drugs.
- Assist in collaboration in updating breakpoints for the best possible patient care and approach to public health.
- Increase understanding about CLSI's role and commitment to ensure updated and new breakpoints are available to clinical laboratories worldwide.
Watch on-demand to learn about how laboratories implement crucial rationale documents in day to day practice and how your laboratory can participate to ensure AST is widely available and timely.
December 17, 2019
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceThis is your member pricing.
Notify Me About New Editions
Scope
Learning Objectives
- Discuss how laboratories and AST device manufacturers need to be able to use up-to-date Susceptibility Test Interpretive Criteria (STIC) or breakpoints for the reports provided to physicians to inform appropriate treatment choices.
- Review how the identification of patients who have certain types of resistant bacteria is also essential for infection control practices.
Previously Titled
Learning Objectives
- Discuss how laboratories and AST device manufacturers need to be able to use up-to-date Susceptibility Test Interpretive Criteria (STIC) or breakpoints for the reports provided to physicians to inform appropriate treatment choices.
- Review how the identification of patients who have certain types of resistant bacteria is also essential for infection control practices.
Scope
Learning Objectives
- Discuss how laboratories and AST device manufacturers need to be able to use up-to-date Susceptibility Test Interpretive Criteria (STIC) or breakpoints for the reports provided to physicians to inform appropriate treatment choices.
- Review how the identification of patients who have certain types of resistant bacteria is also essential for infection control practices.